HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.
August 10, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Werewolf Therapeutics and maintained a $15 price target, which could positively impact the stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and maintenance of a $15 price target by HC Wainwright & Co. indicates their continued confidence in Werewolf Therapeutics, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100